Drugs.com

JANUARY 30, 2024

30, 2024 -- The first new kind of pain medication in over two decades could be on the horizon for patients, with promising results announced Tuesday from a company trial. For now, the drug from Vertex Pharmaceuticals is called VX-548. TUESDAY, Jan.

Pharmaceuticals 286

Pharmaceuticals Trials Drugs 286

Drug Patent Watch

DECEMBER 9, 2024

In the vast realm of pharmaceutical research and development, there’s a fascinating intersection between ancient wisdom and modern science. This intersection is where pharmacognosy meets drug patents, creating a unique landscape that shapes the future of medicine. What is a Drug Patent?

Drugs 94

Drugs Drug Development Pharmaceuticals Production 94

Drug Patent Watch

DECEMBER 12, 2024

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies.

Licensing 89

Licensing Licensing Drugs Biosimilars 89

Drug Patent Watch

JUNE 13, 2025

According to our analysis of clinical trial listings, the following industries are leading the charge in seeking legal counsel: Biotech: With a 25% increase in clinical trial listings over the past year, biotech companies are racing to secure patents and protect their intellectual property.

Clinical Trials 57

Clinical Trials Trials Pharmaceuticals Treatment 57

Drug Target Review

JUNE 11, 2025

Drug development is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates.

Drugs 64

Drugs Clinical Trials Drug Development Pharmaceuticals 64

DrugBank

OCTOBER 30, 2024

At DrugBank, we’re dedicated to empowering pharmaceutical researchers with data that drives impactful results. This lets you focus on what matters most: driving meaningful results in drug research and development.   Enhanced Security and Compliance In the pharmaceutical and healthcare industries, security is paramount.

Production 98

Production Clinical Trials Packaging Compliance 98

Drug Target Review

JULY 3, 2025

It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. This has led drug developers to unintentionally limit their potential within chosen therapeutic spaces.

Drug Development 64

Drug Development Drugs Animal Testing Engineering 64

ProRelix Research

MAY 14, 2025

In the ever-advancing field of pharmaceutical development, regulations surrounding drug clinical trials in the United States serve a critical purpose.

Clinical Trials 52

Clinical Trials Regulations Trials Drugs 52

Drugs.com

MARCH 11, 2024

MONDAY, March 11, 2024 -- Following disappointing trial results, the maker of a controversial ALS drug may pull the medication off the market.In a statement issued Friday, Amylyx Pharmaceuticals said that Relyvrio failed to help patients in a.

Trials 130

Trials Marketing Drugs Pharmaceuticals 130

Drug Patent Watch

DECEMBER 30, 2024

The regulatory environment in Japan for generic drug development is complex and has undergone significant changes in recent years. Regulatory Authority: Pharmaceuticals and Medical Devices Agency (PMDA) The PMDA is the primary regulatory authority responsible for overseeing the drug approval process in Japan.

Drug Development 52

Drug Development Clinical Pharmacology Clinical Trials Pharmaceutical Companies 52

Reprocell

NOVEMBER 27, 2024

In recent years, the pharmaceutical industry has increasingly harnessed artificial intelligence (AI) to make clinical trials more efficient and effective. One of the most powerful applications of AI in this space is its ability to help researchers identify patient groups most likely to benefit from specific drugs.

Clinical Trials 64

Clinical Trials Trials Pharmaceuticals Marketing 64

BioPharma Drive: Drug Pricing

JUNE 4, 2024

Longer follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause of dwarfism may be competitive to an approved therapy from BioMarin Pharmaceutical.

Therapies 182

Therapies Pharmaceuticals Trials Treatment 182

The Pharma Data

JULY 2, 2025

Asahi Kasei Pharma Initiates Phase III Clinical Trial of ART-123 to Combat Chemotherapy-Induced Peripheral Neuropathy Asahi Kasei Pharma Corporation has officially commenced drug administration in a pivotal Phase III clinical trial of ART-123, a recombinant human thrombomodulin (rTM), in Japan.

Trials 40

Trials Clinical Trials Pharmaceuticals Treatment 40

The Pharma Data

JUNE 25, 2025

Biogen Reports Promising Interim Phase 1 Results for Salanersen in Spinal Muscular Atrophy, Prepares for Registrational Trials Biogen has announced encouraging topline results from its Phase 1 clinical trial evaluating salanersen (BIIB115/ION306) , an investigational antisense oligonucleotide (ASO) therapy for spinal muscular atrophy (SMA).

Therapies 52

Therapies Trials RNA Treatment 52

PPD

OCTOBER 31, 2024

As the pharmaceutical industry continues to evolve, drug developers encounter new challenges and opportunities in their pursuit of innovation. From adapting to complex new trial designs to embracing cutting-edge technologies, staying ahead requires a deep understanding of the current landscape.

Drug Development 52

Drug Development Clinical Trials Trials Drugs 52

ProRelix Research

MAY 31, 2023

Introduction: Clinical trials are a crucial component of the pharmaceutical and medical research industry, aimed at evaluating the safety and effectiveness of new drugs, treatments, or medical devices before they […] The post Successful Clinical Trial With ProRelix Research: Phase 1, 2, 3 & 4 Clinical Trial Services at … appeared (..)

Clinical Trials 98

Clinical Trials Trials Research Pharmaceuticals 98

The Pharma Data

JUNE 18, 2025

A Next-Generation Antibody-Drug Conjugate Targeting B7-H3 Ifinatamab deruxtecan is a potential first-in-class antibody-drug conjugate (ADC) specifically engineered to target B7-H3 , a surface protein overexpressed in many solid tumors, including prostate cancer.

Trials 40

Trials Therapies Clinical Trials Treatment 40

Drug Hunter

SEPTEMBER 17, 2023

III clinical trials such as Vertex’s sodium channel inhibitor for acute pain and Denali Therapeutics’ CNS-penetrant eIF2B activator for ALS. selective inhibitor developed by Vertex Pharmaceuticals for acute pain in Phase III clinical trials. The post Molecules of the Month – August 2023 appeared first on Drug Hunter.

Clinical Trials 206

Clinical Trials Trials Therapies Pharmaceuticals 206

Drug Target Review

JUNE 6, 2025

“Protocol development can be a complex and meticulous process,” he explains, “as it’s crucial to ensure that trial candidates meet the necessary inclusion criteria.” Prior treatments and patient histories often introduce variables that can affect outcomes, making thoughtful trial design essential for generating reliable data.

Therapies 100

Therapies Treatment Drug Development Clinical Development 100

Drug Target Review

JUNE 9, 2025

A personal journey to Alltrna Michelle Werner’s career has spanned over 20 years in the pharmaceutical industry, where she developed her expertise in oncology drug development at leading companies such as Bristol Myers Squibb, AstraZeneca, and Novartis.

Disease 80

Disease Treatment Engineering Protein Production 80

PPD

AUGUST 16, 2023

The COVID-19 pandemic rapidly accelerated the adoption of hybrid and decentralized clinical trial (DCT) models. However, as the world settles into its post-pandemic state and returns to pre-pandemic paradigms in many areas, the pharmaceutical industry remains dedicated to moving beyond traditional, centralized clinical trial constructs.

Clinical Trials 98

Clinical Trials Trials Clinical Research FDA 98

Drug Patent Watch

OCTOBER 8, 2024

A recent study published in Drug Discovery Today highlights the potential of artificial intelligence (AI) in revolutionizing drug discovery and development processes[1].

Clinical Trials 116

Clinical Trials Drugs Pharmaceuticals Trials 116

Drug Target Review

JULY 4, 2023

Over the last two decades, an increasing number of Antibody Drug Conjugate (ADC) therapeutics have been approved for oncology indications. These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

New Drug Approvals

APRIL 11, 2025

1] [2] Adverse effects The US Food and Drug Administration prescription label for fitusiran contains a boxed warning for thrombotic events (blood clotting) and gallbladder disease (with some recipients requiring gallbladder removal). [2] Food and Drug Administration. Fitusiran 1711.0g/mol, 1] It is given by subcutaneous injection. [1]

Clinical Trials 107

Clinical Trials FDA FDA Approval Trials 107

Drug Patent Watch

JANUARY 8, 2025

This comprehensive guide will walk you through the intricacies of optimizing your drug patent strategy, ensuring that your innovations are safeguarded and your market position is strengthened. Understanding the Basics of Drug Patents Before diving into the nuances of patent strategy, it’s crucial to grasp the fundamentals.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Licensing Licensing 52

The Pharma Data

JUNE 11, 2025

Ionis Begins Pivotal Phase 3 REVEAL Study of ION582 in Angelman Syndrome, Dosing First Patient in Global Trial Ionis Pharmaceuticals , Inc. This trial will build on previous positive data from the earlier Phase 1/2 HALOS study and is designed to rigorously assess the potential of ION582 as a disease-modifying therapy. “We

Trials 40

Trials Therapies Treatment Disease 40

DrugBank

OCTOBER 4, 2024

Deal Structuring Deal structuring in pharmaceutical M&A requires a balance of financial, legal, and strategic considerations. Intellectual Property Valuation Valuing intellectual property (IP) assets is a critical component of pharmaceutical M&A, as these assets often represent a significant portion of a company's value.

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

The Pharma Data

JUNE 25, 2025

Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc. , a biotechnology firm known for its expertise in microRNA-targeting therapies.

RNA 52

RNA Clinical Trials Disease Small Molecule 52

The Pharma Data

JUNE 23, 2025

Phase 2 Study: Transformative Weight Loss and Glycemic Control The Phase 2 trial focused on evaluating the efficacy and safety of MariTide in individuals with obesity, both with and without Type 2 diabetes (T2D). This schedule reflects the learnings from the Phase 1 PK-LDI trial and aims to maximize tolerability while sustaining efficacy.

Trials 40

Trials Treatment Pharmacokinetics Clinical Trials 40

Chemical Biology and Drug Design

OCTOBER 13, 2024

This review also highlights the challenges in this field which need to be addressed for further successes in pharmaceutical applications. This review focuses on the different AI and machine learning (ML) techniques with their applications mainly focused on the pharmaceutical industry.

Pharmaceuticals 100

Pharmaceuticals Science Clinical Trials Trials 100

The Pharma Data

JUNE 6, 2025

Otsuka Unveils Promising Phase 3 Results for Sibeprenlimab in IgA Nephropathy, Marking Significant Proteinuria Reduction and Advancing a Novel APRIL-Targeted Therapy Otsuka Pharmaceutical Development & Commercialization, Inc., in collaboration with Otsuka Pharmaceutical Co., in collaboration with Otsuka Pharmaceutical Co.,

Trials 40

Trials Treatment FDA Therapies 40

BioPharma Drive: Drug Pricing

JUNE 23, 2025

Originally developed in the 1970s to treat diabetes, these drugs—such as Ozempic, Wegovy, and Mounjaro—have become headline-makers for their ability to induce significant weight loss. Understanding GLP-1 drugs GLP-1, or glucagon-like peptide-1 receptor modulators, mimic natural hormones that regulate insulin and appetite.

Treatment 130

Treatment Drugs Therapies FDA 130

PPD

DECEMBER 16, 2024

Our annual look at the state of the drug development industry highlights a dual set of challenges complicating progress. Pressure and requirements to engage diverse patient populations in trials have become more challenging and expensive, requiring tailored strategies that can stretch both resources and budgets.

Drug Development 52

Drug Development Clinical Trials Compliance Trials 52

Advarra

DECEMBER 17, 2024

For example, AI tools can pull data from protocols and automatically update clinical trial management systems (CTMS), reducing manual entry errors and increasing workflow speed. This same data could be used to auto-generate study calendars based on the schedule of assessments, streamlining trial planning.

Clinical Research 98

Clinical Research Clinical Trials Trials Hospitals 98

Drug Target Review

JULY 7, 2025

Non-human primates (NHPs), such as macaques and cynomolgus monkeys, have long served as a cornerstone in preclinical drug development due to their close genetic, anatomical and physiological resemblance to humans. Conventional models often fail to predict cardiac side effects, especially with biologics.

Drug Research 52

Drug Research Research Animal Testing Drugs 52

PPD

JUNE 7, 2023

The need for pediatric pharmaceuticals and biologics to treat the disease is urgent: Estimates project roughly one in 10 children will be afflicted by NAFLD. Food and Drug Administration (FDA) for approval , much work remains for drug developers aiming to advance treatments for pediatric populations. Hispanic: 11.8%

Trials 98

Trials Clinical Trials Clinical Research Disease 98

DrugBank

OCTOBER 17, 2024

Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drug development lifecycle.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98